New combo therapy targets deadly immune overreaction in lymphoma patients
NCT ID NCT07270835
First seen Jan 04, 2026 · Last updated Apr 30, 2026 · Updated 16 times
Summary
This study tests whether a combination of two drugs, zanubrutinib and rituximab, can control a dangerous immune condition called secondary hemophagocytic lymphohistiocytosis (HLH) that occurs in people with B-cell lymphoma. About 40 participants aged 14-80 will receive the treatment for 4 weeks, along with other supportive medications. The main goal is to see how many patients respond to therapy and survive after 8 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The First Affiliated Hospital of Soochow University
RECRUITINGSuzhou, Jiangsu, China
Contact Email: •••••@•••••
Contact Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.